Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev Chilena Infectol ; 38(1): 31-36, 2021 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-33844790

RESUMO

BACKGROUND: Sepsis is a serious entity. Diagnosis and early treatment is important for the prognosis. AIM: To analyze the prognostic utility of the qSOFA scale as a predictor of mortality in patients admitted by infection in an Internal Medicine Service and describe its demographic characteristics and possible association with mortalilty. METHODS: Descriptive and cross-sectional study of patients admitted with diagnosis of acute infection at the General Hospital of Castellon (Spain) from November 2017 to February 2018. INCLUSION CRITERIA: patients admitted on suspicion of an infectious process. Main dependent variable: mortality. Independent main variable: qSOFA scale. Secondary variables: time until the first medical evaluation and the start of empirical antibiotic therapy, demographic characteristics of the patient, analytics and evolutional. RESULTS: A total of 311 patients were analyzed, 145 men with an average age of 78 (DE 16,23). Seventy five presented qSOFA ≥ 2. Higher mortality was observed in those patients with qSOFA ≥ 2 (36% vs 11%, p = 0.00). CONCLUSION: In patients admitted with infectious diseases, a qSOFA value > = 2 was associated with higher mortality. Future studies are required to verify its potential diagnostic utility.


Assuntos
Doenças Transmissíveis , Sepse , Idoso , Doenças Transmissíveis/diagnóstico , Estudos Transversais , Serviço Hospitalar de Emergência , Mortalidade Hospitalar , Humanos , Masculino , Escores de Disfunção Orgânica , Prognóstico , Curva ROC , Estudos Retrospectivos , Espanha
2.
Rev. chil. infectol ; 38(1): 31-36, feb. 2021. tab
Artigo em Espanhol | LILACS | ID: biblio-1388204

RESUMO

INTRODUCCIÓN: La sepsis es una entidad grave siendo su sospecha y tratamiento precoces claves para el pronóstico. OBJETIVO: Analizar la utilidad pronóstica de la escala qSOFA en pacientes que ingresan por infección en un servicio de Medicina Interna. PACIENTES Y MÉTODOS: Estudio descriptivo, tranversal, de los pacientes ingresados con infección en el Hospital General de Castellón (España) de noviembre de 2017 a febrero de 2018. Criterio de inclusión: pacientes admitidos por la sospecha de un proceso infeccioso. Variable principal dependiente: mortalidad. Variable principal independiente: qSOFA. Variables secundarias: tiempo hasta primera valoración médica y hasta inicio de antibioterapia empírica en Urgencias (minutos), características demográficas del paciente, analíticas y evolutivas. RESULTADOS: Se analizó un total de 311 pacientes, 145 varones, edad media 78 años (DE 16,23). Setenta y cinco (24%) presentaron qSOFA ≥ 2. Se observó una mayor mortalidad en aquellos pacientes con qSOFA ≥ 2 (36 vs 11%, p = 0,00). CONCLUSIÓN: En pacientes admitidos con enfermedades infecciosas, un valor de qSOFA > = 2 se asoció a mayor mortalidad. Se requieren futuros estudios para comprobar su potencial utilidad diagnóstica.


BACKGROUND: Sepsis is a serious entity. Diagnosis and early treatment is important for the prognosis. AIM: To analyze the prognostic utility of the qSOFA scale as a predictor of mortality in patients admitted by infection in an Internal Medicine Service and describe its demographic characteristics and possible association with mortalilty. METHODS: Descriptive and cross-sectional study of patients admitted with diagnosis of acute infection at the General Hospital of Castellon (Spain) from November 2017 to February 2018. Inclusion criteria: patients admitted on suspicion of an infectious process. Main dependent variable: mortality. Independent main variable: qSOFA scale. Secondary variables: time until the first medical evaluation and the start of empirical antibiotic therapy, demographic characteristics of the patient, analytics and evolutional. RESULTS: A total of 311 patients were analyzed, 145 men with an average age of 78 (DE 16,23). Seventy five presented qSOFA ≥ 2. Higher mortality was observed in those patients with qSOFA ≥ 2 (36% vs 11%, p = 0.00). CONCLUSION: In patients admitted with infectious diseases, a qSOFA value > = 2 was associated with higher mortality. Future studies are required to verify its potential diagnostic utility.


Assuntos
Humanos , Masculino , Feminino , Idoso , Doenças Transmissíveis/diagnóstico , Sepse , Prognóstico , Espanha , Estudos Transversais , Estudos Retrospectivos , Curva ROC , Mortalidade Hospitalar , Serviço Hospitalar de Emergência , Escores de Disfunção Orgânica
3.
Rev. esp. quimioter ; 32(5): 445-450, oct. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-188711

RESUMO

INTRODUCCIÓN: Las terapias inmunosupresoras en el tratamiento de las enfermedades inflamatorias mediadas por la inmunidad (EIMI) predisponen a la tuberculosis, por lo que el cribado de infección tuberculosa latente (ITL) y su tratamiento reduce la probabilidad de progresión a tuberculosis activa. El objetivo del estudio fue analizar la concordancia entre la prueba de la tuberculina (PT) e "Interferon Gamma Release Assay-IGRA" en relación con el tipo de EIMI y tratamiento inmunosupresor (IS). MATERIAL Y MÉTODOS: Estudio transversal en pacientes con EIMI candidatos o en tratamiento IS remitidos para cribado de ITL, de Abril del 2017 hasta Mayo del 2018. Variables resultado fueron PT e IGRA. Variables explicativas: EIMI, IS, edad, sexo, vacunación BCG previa y factores de riesgo de tuberculosis. RESULTADOS: Se estudiaron 146 pacientes (33 [22,6%] vacunados con BCG, 1 [0,7%] con diagnóstico previo de tuberculosis y 22 [15,1%] originarios de país endémico). Índice de Kappa (k) fue de 0,338 entre PT e IGRA para la totalidad de la muestra. Menor concordancia en pacientes con enfermedad de Crohn (k=0,125), en los tratados con corticoides (k=0,222), vacunados con BCG (k=0,122) y en pacientes procedentes de países endémicos de tuberculosis (k=0,128). CONCLUSIONES: La concordancia entre la PT y el IGRA se ve afectada en pacientes con EIMI y en mayor medida en la enfermedad inflamatoria intestinal, con la corticoterapia, con la vacunación con BCG o en los procedentes de países endémicos


INTRODUCTION: The immunosuppressive therapies in the treatment of the immune-mediated inflammatory diseases (EIMI) predispose individuals to the tuberculosis, so the screening of latent tuberculosis infection (ITL) and the treatment reduces the likelihood of a progression to an active tuberculosis. The aim of the study was to analyze the concordance between the test of the tuberculin (PT) and "Interferon Gamma Release Assay-IGRA" in relation to the type of EIMI and the immunosuppressive treatment (IS). MATERIAL AND METHODS: Transversal study of patients with EIMI candidates or in treatment IS forwarded to the ITL screening, from April 2017 until May 2018. The outcome variables were PT and IGRA. The explicative variables were: EIMI, IS, age, gender, prior BCG vaccination and tuberculosis risk factors. RESULTS: A total of 146 patients were analyzed (33[22.6%] vaccinated with BCG, 1 [0.7%] with a pre-diagnosis of tuberculosis, and 22 [15.1%] from an endemic country). Kappa index (k) was 0,338 between PT and IGRA for the whole sample. A lower concordance was found in patients with the Crohn's disease (k=0.125), in the ones treated with corticosteroids (k=0.222), vaccinated with BCG (k=0.122) and in patients from tuberculosis endemic countries (k=0.128). CONCLUSION: The concordance between PT and IGRA is affected in patients with EIMI, and to a greater extent to patients with the inflammatory bowel disease, with the corticotherapy, with the BCG vaccination, or in the ones from endemic countries


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Doenças do Sistema Imunitário/tratamento farmacológico , Imunossupressores/efeitos adversos , Tuberculose Latente/diagnóstico , Vacina BCG/efeitos adversos , Doença de Crohn/tratamento farmacológico , Estudos Transversais , Hospedeiro Imunocomprometido , Imunossupressores/uso terapêutico , Testes de Liberação de Interferon-gama , Sensibilidade e Especificidade , Teste Tuberculínico , Corticosteroides/uso terapêutico , Fatores Etários , Artrite Reumatoide/tratamento farmacológico , Vacina BCG/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...